13/04/2016

Biohit Oyj

The scientific report on Biohit’s first smoking intervention trial has been accepted for publication

The scientific report on the first smoking intervention study by Biohit has been accepted for publication in a widespread international journal Anticancer Research. The trial using Acetium lozenge was completed in November 2015. According to the trial, the Acetium lozenge is a promising novel method to assist in smoking cessation.

Chief Medical Director, Professor Kari Syrjänen, Biohit Oyj: ‘Acetium lozenge is a safe promising product for smoking cessation because it is all natural and it does not contain any nicotine. The product has no restrictions for use or a maximum allowable dosage. A smoker can use it simultaneously with cigarettes until making the decision to quit smoking.’

CEO, Semi Korpela, Biohit Oyj: ‘Unlike many commonly used current intervention methods, of which medical treatment can cause severe side effects and nicotine products maintain nicotine addiction, the Acetium lozenge is a product, which has no known side effects. Despite the fact that the product efficiently binds carcinogenic acetaldehyde dissolved into saliva from cigarette smoke, transforming it into a harmless compound, and in addition, promotes oral health, unlike the currently available medications and nicotine products, Biohit Oyj recommends quitting smoking because of the smoking health hazards. As soon as the ethical approval has been obtained Biohit starts a larger trial which aims to confirm the previous promising results of the efficacy of Acetium lozenge as a method to assist in smoking cessation.’

Additional information:

Chief Medical Director of Biohit Oyj, Professor, MD, PhD Kari Syrjänen
kari.syrjanen@biohit.fi

CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

Exhibitor Data Sheet